News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule

/in , /by

A novel dual payload peptide drug conjugate technology, known as the pre|CISION® platform, represents an advance in oncology by delivering two complementary anticancer therapies from a single molecule. This approach leverages the fibroblast activation protein (FAP), which is selectively present in the tumor microenvironment, especially in advanced prostate cancer such as castration-resistant prostate cancer (CRPC). […]

Read more

Helicon Degraders Show a New Path in Prostate Cancer Therapy

/in /by

In one of the most compelling advances for prostate cancer biology in recent years, a novel peptide-based degrader has achieved potent, selective elimination of the transcription factor ERG, an oncogenic driver long considered unreachable by medicinal chemistry. The discovery has upended conventional views on druggability in TMPRSS2–ERG fusion–positive prostate cancers, which comprise nearly half of […]

Read more

KLS-3021: a Promising Oncolytic Virus for Prostate Cancer

/in , /by

KLS-3021 is a novel oncolytic virus therapy developed for the treatment of prostate cancer. It employs a recombinant vaccinia virus engineered to selectively infect and destroy cancer cells while activating the immune system to target tumors more effectively. The virus carries three therapeutic genes: PH-20, which degrades the extracellular matrix to facilitate viral spread and […]

Read more

Rapid Genome Sequencing Redefines Clinical Readiness

/in /by

A collaboration between Broad Clinical Labs, Roche Sequencing Solutions, and Boston Children’s Hospital has set a Guinness World Record for sequencing and analyzing a whole human genome in under four hours. The record, confirmed this month and documented in the New England Journal of Medicine, demonstrates that complete genomic workflows can be completed in less […]

Read more

Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib)

/in /by

Scientists at The Institute of Cancer Research in London have identified a combination therapy that may benefit up to 40 percent of men with advanced prostate cancer, particularly those whose tumors have become resistant to hormone therapies. This approach targets two proteins essential for cancer cell survival: MCL1 and AKT. Direct inhibition of MCL1 has […]

Read more

Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer

/in , /by

A new study published in Nature Signal Transduction and Targeted Therapy reports a major leap in the design of targeted cancer therapies through the development of an in vivo self-assembled nano-PROTAC (proteolysis targeting chimera) system capable of delivering dual-targeted degradation in castration-resistant prostate cancer (CRPC).​ PROTACs have reshaped the drug discovery landscape by inducing selective […]

Read more

Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness

/in /by

Researchers have identified two enzymes that serve as critical guardians of prostate cancer cell survival, opening new avenues for enhancing treatment outcomes in one of the most common cancers affecting men worldwide. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that blocking these molecular chaperones can destabilize cancer cells and […]

Read more

Scientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types

/in , /by

Researchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]

Read more

New Study Uncovers Mechanism Behind T-Cell Exhaustion, Offering Hope for Prostate Cancer Immunotherapy

/in , /by

A study from The Ohio State University Comprehensive Cancer Center has illuminated a critical reason why cancer immunotherapy often fails: T-cell exhaustion driven by a novel stress pathway called TexPSR (proteotoxic stress response in T-cell exhaustion). Published in the prestigious journal Nature, this discovery reveals a proteotoxic shock in exhausted T cells caused by the […]

Read more